Characteristics and Outcome of 18 Patients Receiving Marrow Transplants From Unrelated Donors for Treatment of Ph1+ ALL
| UPN . | Age (y) . | Gender (Pt/D) . | Search Start to BMT (mo) . | Donor HLA-Mismatching . | Disease Stage at BMT . | GVHD . | Relapse (mo) . | Survival (mo) . | |
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | Acute . | Chronic . | . | . |
| 5191 | 25 | M/M | 8.9 | None | 1st Remission | III | Extensive | No | >73.0 |
| 7361 | 47 | F/F | 3.6 | None | 1st Remission | II | Extensive | No | >41.5 |
| 8124 | 26 | M/F | 2.5 | None | 1st Remission | II | No | No | >24.7 |
| 9115 | 3 | F/M | 4.8 | None | 1st Remission | III | Extensive | No | >17.1 |
| 9222 | 1.7 | M/F | 3.8 | None | 1st Remission | II | Extensive | No | >16.5 |
| 8278 | 43 | F/F | 6.1 | None | 1st Remission | I | Extensive | No | 9.6 |
| 9861 | 51 | M/M | 4.5 | None | 1st Remission | I | No | No | >9.3 |
| 9833 | 34 | M/M | 2.9 | None | 2nd Remission | I | Limited | No | >9.0 |
| 7958 | 20 | M/M | 4.0 | DRB1* | 1st Relapse† | II | Extensive | No | >31.4 |
| 9635 | 29 | M/M | 3.5 | None | 1st Relapse‡ | II | Extensive | No | >12.6 |
| 4637 | 43 | M/M | 2.6 | None | 1st Relapse | II | NA | 1.9 | 4.0 |
| 8765 | 47 | F/F | 5.9 | Aρ | 2nd Relapse | I | No | 4.5 | 5.2 |
| 6642 | 8 | F/M | 4.9 | B* | 2nd Relapse | IV | NA | No | 2.0 |
| 8650 | 20 | M/M | 4.1 | DRB1ρ | 2nd Relapse | NA | NA | No | 0.1 |
| 6056 | 19 | F/F | 3.0 | DRB1* | 3rd Relapse | III | NA | 3.2 | 3.7 |
| 5942 | 35 | F/M | 5.6 | B* | 3rd Relapse | IV | NA | No | 2.5 |
| 4838 | 21 | F/M | 11.7 | None | 4th Relapse | III | No | 3.9 | 4.2 |
| 7841 | 25 | M/M | 8.3 | DRB1* | Induction failure | II | No | 3.6 | 4.9 |
| UPN . | Age (y) . | Gender (Pt/D) . | Search Start to BMT (mo) . | Donor HLA-Mismatching . | Disease Stage at BMT . | GVHD . | Relapse (mo) . | Survival (mo) . | |
|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | . | . | Acute . | Chronic . | . | . |
| 5191 | 25 | M/M | 8.9 | None | 1st Remission | III | Extensive | No | >73.0 |
| 7361 | 47 | F/F | 3.6 | None | 1st Remission | II | Extensive | No | >41.5 |
| 8124 | 26 | M/F | 2.5 | None | 1st Remission | II | No | No | >24.7 |
| 9115 | 3 | F/M | 4.8 | None | 1st Remission | III | Extensive | No | >17.1 |
| 9222 | 1.7 | M/F | 3.8 | None | 1st Remission | II | Extensive | No | >16.5 |
| 8278 | 43 | F/F | 6.1 | None | 1st Remission | I | Extensive | No | 9.6 |
| 9861 | 51 | M/M | 4.5 | None | 1st Remission | I | No | No | >9.3 |
| 9833 | 34 | M/M | 2.9 | None | 2nd Remission | I | Limited | No | >9.0 |
| 7958 | 20 | M/M | 4.0 | DRB1* | 1st Relapse† | II | Extensive | No | >31.4 |
| 9635 | 29 | M/M | 3.5 | None | 1st Relapse‡ | II | Extensive | No | >12.6 |
| 4637 | 43 | M/M | 2.6 | None | 1st Relapse | II | NA | 1.9 | 4.0 |
| 8765 | 47 | F/F | 5.9 | Aρ | 2nd Relapse | I | No | 4.5 | 5.2 |
| 6642 | 8 | F/M | 4.9 | B* | 2nd Relapse | IV | NA | No | 2.0 |
| 8650 | 20 | M/M | 4.1 | DRB1ρ | 2nd Relapse | NA | NA | No | 0.1 |
| 6056 | 19 | F/F | 3.0 | DRB1* | 3rd Relapse | III | NA | 3.2 | 3.7 |
| 5942 | 35 | F/M | 5.6 | B* | 3rd Relapse | IV | NA | No | 2.5 |
| 4838 | 21 | F/M | 11.7 | None | 4th Relapse | III | No | 3.9 | 4.2 |
| 7841 | 25 | M/M | 8.3 | DRB1* | Induction failure | II | No | 3.6 | 4.9 |
Abbreviations: BMT, bone marrow transplant; CR1, first complete remission; D, donor; NA, not applicable; Pt, patient; UPN, unique patient number.
Minor mismatch defined as a single disparity for HLA-A or HLA-B antigens belonging to the same cross-reactive group, or for a single DRB1 disparity for subtype alleles within the same DR specificity.
Transplanted in CNS relapse and marrow remission.
Transplanted with 11% blasts in the marrow. The blank line separates patients in complete remission at transplantation from those with primary refractory or relapsed leukemia.
ρ One-antigen mismatch defined as a single disparity not fullfilling the criteria for minor mismatch.